Basic information Safety Supplier Related
ChemicalBook >  Product Catalog >  Biochemical Engineering >  Inhibitors >  PI3K / Akt / mTOR >  Akt inhibitors >  GSK-2110183C

GSK-2110183C

Basic information Safety Supplier Related

GSK-2110183C Basic information

Product Name:
GSK-2110183C
Synonyms:
  • Afuresertib(GSK2110183C)
  • Afuresertib
  • GSK 2110183C
  • GSK2110183C
  • GSK-2110183C
  • N-((S)-1-amino-3-(3-fluorophenyl)propan-2-yl)-5-chloro-4-(4-chloro-1-methyl-1H-pyrazol-5-yl)thiophene-2-carboxamide
  • Afuresertib, GSK-2110183, GSK-2110183B
  • Delitinib
CAS:
1047644-62-1
MF:
C18H17Cl2FN4OS
MW:
427.32
EINECS:
1592732-453-0
Product Categories:
  • Inhibitors
Mol File:
1047644-62-1.mol
More
Less

GSK-2110183C Chemical Properties

Boiling point:
535.1±50.0 °C(Predicted)
Density 
1.49±0.1 g/cm3(Predicted)
storage temp. 
Store at -20°C, protect from light, stored under nitrogen
solubility 
DMSO:62.5(Max Conc. mg/mL);146.26(Max Conc. mM)
Ethanol:85.0(Max Conc. mg/mL);198.91(Max Conc. mM)
pka
13.03±0.46(Predicted)
form 
Powder
color 
White to off-white
InChI
InChI=1S/C18H17Cl2FN4OS/c1-25-16(14(19)9-23-25)13-7-15(27-17(13)20)18(26)24-12(8-22)6-10-3-2-4-11(21)5-10/h2-5,7,9,12H,6,8,22H2,1H3,(H,24,26)/t12-/m0/s1
InChIKey
AFJRDFWMXUECEW-LBPRGKRZSA-N
SMILES
C1(C(N[C@@H](CC2=CC=CC(F)=C2)CN)=O)SC(Cl)=C(C2N(C)N=CC=2Cl)C=1
More
Less

GSK-2110183C Usage And Synthesis

Uses

Afuresertib is a potent pan-AKT inhibitor that demonstrated synergy with bortezomib in preclinical models of multiple myeloma.

Definition

ChEBI: N-[(2S)-1-amino-3-(3-fluorophenyl)propan-2-yl]-5-chloro-4-(4-chloro-2-methyl-3-pyrazolyl)-2-thiophenecarboxamide is a member of amphetamines.

in vivo

Mice bearing BT474 breast tumor xenografts are dosed orally with either vehicle or GSK2110183 at 10, 30 or 100 mg/kg daily for 21 days which result in 8, 37 and 61% TGI, respectively. Mice tolerated GSK2110183 well, with 1-3% body weight loss reported after 5 days of dosing which recover over the course of the study. Other tumor xenograft models which possess an activation of the Akt pathway are explored to further demonstrate compound efficacy. Mice treated with GSK2110183 at 10, 30 and 100 mg/kg result in 23, 37 and 97% TGI, respectively, of SKOV3 xenografts[1].

IC 50

Akt2: 2 nM (Ki); Akt3: 2.6 nM (Ki); Akt1 E17K mutant: 0.2 nM (IC50); PKCη: 210 nM (IC50); PKC-βI: 430 nM (IC50); PKCθ: 510 nM (IC50); ROCK: 100 nM (IC50)

GSK-2110183CSupplier

SuZhou GoodChemTech Co., Ltd Gold
Tel
18136139868; 18136139868
Email
jinlun@goodchemtech.cn
Shanghai Boyle Chemical Co., Ltd.
Tel
Email
sales@boylechem.com
Chembest Research Laboratories Limited
Tel
+86-21-20908456
Email
sales@BioChemBest.com
Beijing Ouhe Technology Co., Ltd
Tel
010-010-82967028 13522913783
Email
2355560935@qq.com
WUHAN SUN-SHINE BIO-TECHNOLOGY Co., Ltd.
Tel
17702719238 18971495150;
Email
sales@sun-shinechem.com